Pharmafile Logo
Pharmafocus logo
Advanced Search
sos002

Sosei Heptares and Metrion Biosciences to collaborate on structure-based drug discovery approaches to ion channels

February 1, 2021
Sales and Marketing Sosei Heptares

Sosei Heptares has announced it will collaborate with Metrion Biosciences, a specialist ion channel CRO and drug discovery company, to …

News
novartis_window

CHMP recommends marketing authorisation for Novartis’ Kesimpta

February 1, 2021
Sales and Marketing Novartis, multiple sclerosis

The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended the marketing authorisation of Novartis’ Kesimpta (ofatumumab) for …

News
top_10_image_2_9

Pharmafile.com’s top 10 news stories of the week

January 29, 2021
Medical Communications

Most of Pharmafile.com’s top stories this week concern the approval of various treatments in the US, UK, and EU – …

News
astrazeneca-sign

AstraZeneca COVID-19 vaccine not for over 65s, German health body says

January 29, 2021
Medical Communications AstraZeneca, COVID-19

Germany’s main public health body has recommended that AstraZeneca’s COVID-19 vaccine is only administered to those aged between 18 and …

News
novavax

Novavax COVID-19 vaccine shows almost 90% efficacy in Phase III trial

January 29, 2021
Medical Communications COVID-19, Novavax

Novavax has announced that its COVID-19 vaccine candidate, NVX-CoV2373, demonstrated an efficacy of 89.3% in its UK Phase III trial. …

News
leiden

Toxys and Leiden University to commercialise and develop animal-free toxicity testing platform

January 29, 2021
Medical Communications Toxys

Toxys, Leiden University, and Leiden University Medical Center have agreed to commercialise and develop further the ToxProfiler technology invented at …

News
opaganib-bottle-and-tablets

RedHill expands manufacturing capacity for opaganib with Cosmo

January 29, 2021
Medical Communications RedHill Biopharma

RedHill Biopharma has announced a manufacturing agreement with Cosmo Pharmaceuticals to further expand manufacturing capacity for opaganib (Yeliva), to address …

News
oxbryta-bottle-and-pills

EMA accepts Global Blood Therapeutics’ MAA for Oxbryta

January 28, 2021
Global Blood Therapeutics

The EMA has accepted Global Blood Therapeutics (GBT)’s Marketing Authorisation Application (MAA) for Oxbryta (voxelotor) tablets, and has started its …

News
pfizer_building_logo1

Pfizer-BioNTech COVID-19 vaccine effective against South Africa variant, companies say

January 28, 2021

Pfizer and BioNTech have said that their COVID-19 vaccine is effective in protecting against the variant of the virus found …

News
china_flag

Harbour BioMed’s Batoclimab granted Breakthrough Therapy designation in China

January 28, 2021
Harbour BioMed

Harbour BioMed (HBM) has announced that China’s Center for Drug Evaluation (CDE) has granted Breakthrough Therapy designation to Batoclimab, a …

News

Pfizer’s rheumatoid arthritis drug fails to meet safety criteria

January 28, 2021
Pfizer

Pfizer has announced that its rheumatoid arthritis (RA) drug XELJANZ (tofacitinib) has failed to meet the co-primary endpoint in its …

News
valneva

Valneva begins production of its COVID-19 vaccine

January 28, 2021
COVID-19, Valneva

Valneva, a specialty vaccine company focused on the prevention of infectious diseases with significant unmet medical needs, has commenced production …

News
celgene_building

NICE recommends Celgene’s REVLIMID for multiple myeloma

January 27, 2021
Research and Development Cancer, Celgene

NICE has issued a Final Appraisal Document (FAD) recommending Celgene’s REVLIMID (lenalidomide) as maintenance treatment after an autologous stem cell …

News

Diurnal and Citrine sign licensing agreement for Alkindi

January 27, 2021
Research and Development Citrine, Diurnal

Diurnal Group has entered into an exclusive licence agreement for its product Alkindi (hydrocortisone granules in capsules for opening) with …

News
european_commission_web

MSD’s cancer therapy KEYTRUDA gets EU approval

January 26, 2021
Manufacturing and Production Cancer, MSD

MSD, known as Merck in the US and Canada, has received approval from the European Commission (EC) for its anti-PD-1 …

News
fdaoutsideweb

FDA approves Aurinia’s oral lupus nephritis therapy

January 26, 2021
Manufacturing and Production Aurinia

The FDA has approved Aurinia Pharmaceuticals’ LUPKYNIS (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients …

News
astrazeneca_building_white

AstraZeneca rejects “incorrect” claims about COVID-19 vaccine efficacy

January 26, 2021
Manufacturing and Production AstraZeneca, COVID-19

AstraZeneca has rejected claims by German media that its COVID-19 vaccine has only 8% efficacy in over-65s. Two German newspapers, …

News
merckincweb

MSD discontinues development of COVID-19 vaccines

January 26, 2021
Manufacturing and Production MSD, Merck

Merck, known as MSD outside of the US and Canada, has announced that the company is discontinuing development of its …

News
abbvie_0

AbbVie’s psoriatic arthritis and ankylosing spondylitis drug gets EU approval

January 26, 2021
Manufacturing and Production AbbVie

The European Commission (EC) has approved AbbVie’s RINVOQTM (upadacitinib 15 mg), an oral, once-daily selective and reversible JAK inhibitor for …

News
drug-trials

How COVID-19 has affected the oncology drugs market

January 25, 2021
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COVID-19, Cancer

In its disruption to clinical trials and drug supply to patients, the COVID-19 pandemic has impacted the most crucial areas …

Feature
The Gateway to Local Adoption Series

Latest content

Alto Neuroscience announces new patent for depression treatment

January 15, 2026

Arkin Capital closes $100m fund for pre-clinical and early clinical-stage biotech

January 15, 2026

Bio-Sourcing and Zerion Pharma receive 1.3m euros in funding for joint breast cancer project

January 14, 2026

Biocartis announces breast cancer research collaboration with US Mayo Clinic

January 14, 2026

Blue Earth announces first UK patient received prostate cancer injection

January 13, 2026